Document Detail


Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats.
MedLine Citation:
PMID:  8640347     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. The time-course and comparative effects of treatment with clofibrate (CFB), bezafibrate (BFB), and gemfibrozil (GFB) on the acyl composition of the main microsomal phospholipids, i.e. phosphatidylcholine and phosphatidylethanolamine, have been studied in male Sprague-Dawley rats. 2. The administration of the three fibrates caused a strong peroxisomal induction and a hypolipidaemic effect. Concerning the changes in acyl composition, CFB and BFB behaved in a similar way, with differences which could be attributed to their different potency as peroxisome inducers, whereas GFB showed a somewhat distinct profile. 3. The three drugs increased the relative content of palmitic, palmitoleic and oleic acids, whereas the levels of stearic acid and also those of long chain, highly unsaturated fatty acids docosatetraenoic, docosapentaenoic and docosahexaenoic acids were reduced. In general, these effects appeared from the first day of treatment and were highly correlated with peroxisomal proliferation. In addition, they were more evident in the phosphatidylcholine than in the phosphatidylethanolamine fraction. 4. Fibrates increased total monounsaturated fatty acids, whereas a decrease in total polyunsaturated fatty acids in the phosphatidylcholine fraction was observed in CFB- and BFB-, but not in GFB-treated rats. Clear differences appeared between CFB and BFB on the one hand, and GFB on the other when the influence of fibrate treatment on the molar percentages of linoleic, eicosatrienoic, arachidonic and mead acids was analyzed. 5. GFB increased linoleic acid content in phosphatidylethanolamine, whereas CFB and BFB decreased its level in both phospholipid fractions. In contrast, CFB and BFB enhanced eicosatrienoic and mead acids in both fractions and arachidonic acid in phosphatidylethanolamine, whereas GFB had practically no effect.
Authors:
M Vázquez; S Muñoz; M Alegret; T Adzet; M Merlos; J C Laguna
Related Documents :
2001227 - Modification of host cell membrane lipid composition by the intra-erythrocytic human ma...
22796217 - Folic acid and cell-penetrating peptide conjugated plga-peg bifunctional nanoparticles ...
24115227 - A model of in vitro udp-glucuronosyltransferases inhibition by bile acids predicts poss...
6446577 - Membrane structure-function relationships in cell-mediated cytolysis. i. effect of exog...
12627387 - Proteomic analysis of lactococcus lactis, a lactic acid bacterium.
23186197 - The addition of ticarcillin-clavulanic acid to inra 96 extender for stallion semen cool...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  116     ISSN:  0007-1188     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  1995 Oct 
Date Detail:
Created Date:  1996-07-18     Completed Date:  1996-07-18     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  2067-75     Citation Subset:  IM    
Affiliation:
Dept. Farmacología y Química Terapeutica, Facultad de Farmacia, Núcleo Universitario de Pedralbes, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antilipemic Agents / pharmacology*
Bezafibrate / pharmacology
Cell Division / drug effects
Clofibrate / pharmacology
Dose-Response Relationship, Drug
Fatty Acids, Unsaturated / administration & dosage,  metabolism*
Gemfibrozil / pharmacology
Lipids / blood
Liver / cytology,  drug effects
Male
Microbodies / metabolism
Phosphatidylcholines / metabolism*
Phosphatidylethanolamines / metabolism*
Rats
Rats, Sprague-Dawley
Time Factors
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Fatty Acids, Unsaturated; 0/Lipids; 0/Phosphatidylcholines; 0/Phosphatidylethanolamines; 25812-30-0/Gemfibrozil; 41859-67-0/Bezafibrate; 637-07-0/Clofibrate
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Determination of KA values by controlled receptor expression in Xenopus oocytes.
Next Document:  New high affinity peptide antagonists to the spinal galanin receptor.